

TRAINING UPDATE

Lab Location: SGAH & WAH
Department: Chemistry

Date Distributed: 2/27/2014
Due Date: 3/15/2014
Implementation: 3/1/2014

DESCRIPTION OF PROCEDURE REVISION

Name of procedure:
Alkaline Phosphatase by Dimension Vista® System SGAH.C864 / WAH.C863 v0 Dimension Vista Limits Chart AG.F200v4
Description of change(s):
New Reagent ALPI This SOP and revised form will be implemented on March 1, 2014

Document your compliance with this training update by taking the quiz in the MTS system.

Approved draft for training all sites (version 0)

Technical SOP

Title	Alkaline Phosphatase by Dimension Vista® System	
Prepared by	Ashkan Chini	Date: 2/5/2014
Owner	Robert SanLuis	Date: 2/5/2014

Laboratory Approval		Local Effective Date:
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		

Review		
Print Name	Signature	Date

TABLE OF CONTENTS

1. Test Information.....3
 2. Analytical Principle4
 3. Specimen Requirements.....4
 4. Reagents.....5
 5. Calibrators/Standards.....6
 6. Quality Control7
 7. Equipment And Supplies10
 8. Procedure10
 9. Calculations.....11
 10. Reporting Results And Repeat Criteria.....11
 11. Expected Values.....12
 12. Clinical Significance.....13
 13. Procedure Notes13
 14. Limitations Of Method13
 15. Safety14
 16. Related Documents15
 17. References.....15
 18. Revision History15
 19. Addenda15

1. TEST INFORMATION

Assay	Method/Instrument	Local Code
Alkaline Phosphatase	Dimension Vista® System	ALKPH


Synonyms/Abbreviations
Alk Phos, ALP

Department
Chemistry

Form revised 3/31/00

2. ANALYTICAL PRINCIPLE

Alkaline phosphatase catalyzes the transphosphorylation of p-nitrophenylphosphate (p-NPP) to p-nitrophenol (p-NP) in the presence of the transphosphorylating buffer, 2-amino-2-methyl-1-propanol (AMP). The reaction is enhanced through the use of magnesium and zinc ions. The change in absorbance at 405 nm due to the formation of p-NP is directly proportional to the ALP activity, since other reactants are present in non-rate limiting quantities and is measured using a bichromatic (405, 700 nm) rate technique.



3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type -Preferred -Other Acceptable	Plasma (Heparin) Serum
Collection Container	Plasma: Green top tube Serum: Red top tube, Serum separator tube (SST)
Volume - Optimum - Minimum	1.0 mL 0.5 mL
Transport Container and Temperature	Collection container or Plastic vial at room temperature
Stability & Storage Requirements	Room Temperature: 8 hours
	Refrigerated: 7 days
	Frozen: 6 months
	Instrument on board aliquot stability 2 hours
Timing Considerations	Serum should be physically separated from cells as soon as possible with a maximum limit of two hours from the time of collection.

Criteria	
Unacceptable Specimens & Actions to Take	Specimens that are unlabeled, improperly labeled, or those that do not meet the stated criteria are unacceptable. Request a recollection and credit the test with the appropriate LIS English text code for “test not performed” message. Examples: Quantity not sufficient-QNS; Wrong collection-UNAC. Document the request for recollection in the LIS.
Compromising Physical Characteristics	Gross hemolysis. Reject sample and request a recollection. Credit the test with the appropriate LIS English text code explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to centrifugation.

4. REAGENTS

Refer to the Material Safety Data Sheet (MSDS) supplied with the reagents for complete safety hazards. Refer to the section in this procedure covering “SAFETY” for additional information.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
ALPI	Siemens, Flex® reagent cartridge, Cat. No. K2115
Enzyme Diluent	Siemens Diagnostics Healthcare, REF No. 790035901

4.2 Reagent Preparation and Storage

NOTES: Each container must be labeled with (1) substance name, (2) lot number, (3) expiration date, (4) any special storage instructions; check for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

Refer to the Material Safety Data Sheet (MSDS) for a complete description of hazards. If a specific hazard is present, it will be noted in this procedure when the hazard is first encountered in a procedural step.

Reagent	ALPI
Container	Reagent cartridge
Storage	Store at 2-8° C
Stability	<ul style="list-style-type: none"> Reagent is stable until expiration date stamped on the reagent cartridges. Sealed wells on the instrument are stable for 30 days. Once wells 1 - 8 have been entered by the instrument, they are stable for 2 days. Once wells 9 -12 have been entered by the instrument, they are stable for 4 days.
Preparation	All reagents are liquid and ready to use.

Reagent	Enzyme Diluent
Container	Manufacturer supplied vial
Storage	Store at 2-8° C before and after reconstitution
Stability	<ul style="list-style-type: none"> • Unreconstituted product is stable until expiration date stamped on the vial. • Reconstituted product is stable for 7 days following reconstitution or immediately if visible turbidity appears.
Preparation	<ul style="list-style-type: none"> • Remove vial from refrigerator and proceed directly with next step. • Remove stopper and volumetrically add 10.0 mL of reagent grade water. • Replace stopper and invert gently 10 times. • Sit vials for 15 minutes, then invert gently 10 times. • Sit vials for an additional 15 minutes, then invert 10 times and swirl gently. • Use immediately or store at 2-8° C.

5. CALIBRATORS/STANDARDS

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
ALPI CAL	Siemens Dimension Vista®, Cat. No. KC331

5.2 Calibrator Preparation and Storage

NOTE: Date and initial all calibrators upon opening. Each container must be labeled with (1) substance name, (2) lot number, (3) date of preparation, (4) expiration date, (5) any special storage instructions; check for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

Calibrator	ALPI CAL
Preparation	Calibrator is ready for use. No preparation is required.
Storage/Stability	<ul style="list-style-type: none"> • Store at 2 - 8° C • Unopened calibrator is stable until expiration date stamped on the box. • Opened Calibrator: once the stopper of the vial is punctured, assigned values are stable for 7 days when stored on board the Dimension Vista System.

5.3 Calibration Parameter

Criteria	Special Notations
Reference Material	ALPI CAL

Form revised 3/31/00

Assay Range	10 – 1000 U/L
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in U/L
Frequency	<ul style="list-style-type: none"> • Every new reagent cartridge lot. • Every 90 days for any one lot • When major maintenance is performed on the analyzer. • When control data indicates a significant shift in assay.
Calibration Scheme	2 levels, n = 5

5.4 Calibration Procedure

Auto Calibration:

1. Place the required calibrator vials in a carrier. Make sure the barcode labels are entirely visible through the slots.
2. Place the carrier in the loading area.
3. Position the carrier with the labels facing away from the user.
4. Press the **Load** button.
5. Automatic calibration requires that calibrators be on the instrument. As the time for processing approaches, the instrument reviews onboard inventory for the appropriate calibrators.

Manual Calibration:

1. Verify that calibrators and reagents are in inventory on the instrument.
2. Press **System > Method Summary > Calibration**.
3. Select a method from the sidebar menu. Press the **Order Calibration** button on the screen.
4. Verify that the information on the screen is correct. Verify that the calibrator lot is correct using the drop-down menu.
 - a. When calibrating using Vials press **OK**.
 - b. When calibrating using Cups, check the Use Cups box. This displays the rack and cup position fields. For additional cups use the positions in ascending order. Be sure to use the number of calibration levels and cups as specified in the method IFU. Scan the rack barcode and place calibrator cups in an adapter in position 1 on a rack. Press **OK** and load the rack on the instrument.
5. The status field in the calibration screen changes sequentially to Awaiting Scheduling, Preparing Calibrators and Processing.

5.5 Tolerance Limits

IF.....	THEN.....
If result fall within assay-specific specification, and QC values are within acceptable limits,	proceed with analysis
If result falls outside assay-specific specification, or QC values are out of Acceptable limits,	troubleshoot the assay and/or instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
Liquichek™ Unassayed Chemistry Control Levels 1 and 2	Bio-Rad Laboratories Cat. No. 691 and 692

6.2 Control Preparation and Storage

NOTE: Date and initial all controls upon opening. Each container should be labeled with (1) substance name, (2) lot number, (3) date of preparation, (4) expiration date, (5) initials of tech, and (6) any special storage instructions; check for visible signs of degradation.

Control	Liquichek Unassayed Chemistry Controls, Level 1 and 2
Preparation	Allow the frozen control to stand at room temperature (18-25°C) until completely thawed. Swirl the contents gently to ensure homogeneity. (Do not use a mechanical mixer) Use immediately. After each use, promptly replace the stopper and return to 2-8°C storage.
Storage/Stability	Once the control is thawed, all analytes will be stable for 6 days at 2-8°C. Unthawed controls are stable until the expiration date at -20 to -70°C.

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Dimension Vista® QC Schedule in the Laboratory policy Quality Control Program and in the Dimension Vista® Quick Reference Guide.

6.4 Tolerance Limits

Step	Action
1	Acceptable ranges for QC are programmed into the Laboratory Information System (LIS), and may be posted near the instrument for use during computer downtime.
2	Run Rejection Criteria <ul style="list-style-type: none"> Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported. The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.
3	Corrective Action: <ul style="list-style-type: none"> All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be <u>reanalyzed according to the Laboratory QC Program</u>. Supervisors may override rejection of partial or complete runs only with detailed

Form revised 3/31/00

Step	Action
	<p>documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program.</p> <ul style="list-style-type: none"> • Corrective action documentation must follow the Laboratory Quality Control Program.
4	<p>Review of QC</p> <ul style="list-style-type: none"> • QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee. • If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.

6.5 Review Patient Data

Technologist must review each result with error messages. Refer to the Dimension Vista® system manual “Error messages” section for troubleshooting. Check for unusual patterns, trends, or distributions in patient results (such as an unusually high percentage of abnormal results). Resolve any problems noted before issuing patient reports.

6.6 Documentation

- QC tolerance limits are programmed into the instrument and the LIS. The LIS calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.7 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

Form revised 3/31/00

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform
 Dimension Vista® System

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -70°C.
- Centrifuge

7.3 Supplies

- Aliquot Plates
- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

8. PROCEDURE

ALPI Flex® reagent cartridge Cat. No. K2115 is required to perform this test.

Alkaline Phosphatase is performed on the Dimension Vista® System after the method is calibrated (see Reference Material in Calibration section) and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

8.1	Sample Processing
1.	A sample rack holding tubes or cups is placed on the rack input lane.
2.	The sample shuttle moves the rack to the barcode reader which identifies the rack and samples to the system.
3.	The rack moves into the sample server and to the rack positioner.
4.	At the same time, aliquot plates move from the aliquot loader into position.
5.	The aliquot probe aspirates the sample from the tubes or cups and dispenses it into the wells of the aliquot plates.
6.	After each aspirate-dispense action, the probe is thoroughly rinsed inside and out to prevent sample carryover.
7.	When sample aspiration is completed, the sample server moves the rack back to the sample shuttle, where it is placed on the output lane and can be removed by the operator.

Form revised 3/31/00

8.2	Specimen Testing
1.	For QC placement and frequency, refer to the Dimension Vista® QC Schedule in the Laboratory QC Program.
2.	Follow the instructions, outlined in the Dimension Vista® Operator’s Manual
3.	The instrument reporting system contains error messages to warn the user of specific malfunctions. Results followed by such error messages should be held for follow-up. Refer to the Dimension Vista® system manual “Error messages” section for troubleshooting.
4.	Follow protocol in Section 10.5 “Repeat criteria and resulting” for samples with results above or below the Analytical Measurement Range (AMR). Investigate any failed delta result and repeat, if necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

Test Conditions	
Sample Volume:	3.48 µL
Reagent 1 Volume:	43.48 µL
Reagent 2 Volume:	27.4 µL
Diluent Volume:	99.54 µL
Reaction Time:	7.2 minutes
Test Temperature:	37° C
Wavelength:	405 & 700 nm
Type of measurement:	Bichromatic rate

9. CALCULATIONS

The instrument automatically calculates the concentration of Alkaline Phosphatase in U/L.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

10.3 Units of Measure

U/L

10.4 Clinically Reportable Range (CRR)

10 – 10,000 U/L

10.5 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall within the AMR or CRR may be reported without repeat. Values that fall outside these ranges must be repeated.

IF the result is ...	THEN...
< 10 U/L	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as: < 10 U/L
≥ 1,000 U/L	On Board Automated Dilution: Results ≥ 1,000 U/L will automatically have repeat testing performed into the instrument using dilution factor of 2.33. No multiplication is necessary.
> 2,330 U/L	Manual Dilution: Using the primary tube, make the smallest dilution possible to bring the raw data within the AMR. Maximum allowable dilution: x 10 Diluent: Enzyme Diluent Enter dilution factor as a whole number on the “Enter Sample Data” screen.
> 10,000 U/L	If the recommended dilution does not give results within the clinically reportable range, report as: “> 10,000 U/L -REP” Bring to the attention of your supervisor prior to releasing result.

Message	Code
Verified by repeat analysis	Append –REP to the result.

11. EXPECTED VALUES

11.1 Reference Ranges

Age	Female	Male
Adult (>18 years):	38-136 U/L	38-136 U/L
Pediatric:		
0–7 days	107-357	121-351
8 – 30 days	107-474	138-486
1 – 3 months	125-547	101-467
4 – 6 months	125-449	94-425
7 – 11 months	101-431	101-394
1 – 3 years	185-383	185-383
4 – 6 years	191-450	191-450
7 – 9 years	218-499	218-499
10 – 11 years	169-657	174-624

12 – 13 years	141-499	245-584
14 – 15 years	103-283	169-618
16 – 18 years	82-169	93-317

11.2 Critical Values
 None established.

11.3 Priority 3 Limit(s)
 None established

12. CLINICAL SIGNIFICANCE

Serum alkaline phosphatase levels are of interest in the diagnosis of hepatobiliary disorders and bone disease associated with increased osteoblastic activity. Moderate elevations of alkaline phosphatase may be seen in several conditions that do not involve the liver or bone. Among these are Hodgkin’s disease, congestive heart failure, ulcerative colitis, regional enteritis, and intra-abdominal bacterial infections. Elevations are also observed during the third trimester of pregnancy.

13. PROCEDURE NOTES

- **FDA Status:** FDA Approved/cleared
- **Validated Test Modifications:** None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up. Refer to your Dimension Vista Operator’s Guide.

The expected maximum observed standard deviations for repeatability using n = 5 replicates at the following analyte concentrations are:

ALPI Concentration	Acceptable S.D. Maximum
80 U/L	9 U/L
400 U/L	27 U/L

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)
 10 – 1000 U/L

14.2 Precision

Material	Mean U/L	Standard Deviation (%CV)	
		Repeatability	Within-Lab
Multiquel Unassayed Control			
Level 1	34	1.0 (2.9)	1.4 (4.1)
Level 2	155	1.9 (1.2)	3.1 (2.0)
Level 3	301	4.0 (1.3)	4.6 (1.5)

Form revised 3/31/00

Serum Pool Level 1	78	1.3 (1.7)	1.5 (1.9)
Serum Pool Level 2	833	13.6 (1.6)	15 (1.8)

14.3 Interfering Substances

Triglycerides above 1000 mg/dL tripped a test message: interference could not be determined.

Lipemia at 500 mg/dL and above tripped a test report message: Interference could not be determined.

HIL Interference:

The ALPI method was evaluated for interference according to CLSI/NCCLS EP7-A2. Bias is the difference in the results between the control sample (without the interferent) and the test sample (contains the interferent) expressed in percent.

Bias exceeding 10% is considered interference.

Substance tested	Substance Concentration	ALPI U/L	Bias %
Hemoglobin (hemolysate)	1000 mg/dL	278, 787	<10
Bilirubin (unconjugated)	60 mg/dL	269, 804	<10
Bilirubin (conjugated)	60 mg/dL	268, 799	<10
Lipemia (Intralipid®)	400 mg/dL	298, 849	<10
	500 mg/dL	299, 850	

14.4 Clinical Sensitivity/Specificity/Predictive Values

Not available

15. SAFETY

The employee has direct responsibility to avoid injury and illness at work. Nearly all harmful exposures to infectious substances and chemicals, and other injuries, can be avoided with effective training and consistent safe work practices.

Become familiar with the Environmental Health and Safety (EHS) Manual to learn the requirements on working safely and protecting the environment from harm.

Although lab work typically focuses on the hazards of working with specimens and chemicals, we must also control other important hazards.

- Slips, trips, and falls cause many serious injuries. Please ensure that spills are cleaned quickly (to avoid slippery floors) and that you can see and avoid obstacles in your path.
- Ergonomic injuries result from performing tasks with too much repetition, force, or awkward position. Ergonomic injuries include strains and back injuries. Learn about ergonomic hazards and how to prevent this type of injury.
- Scratches, lacerations, and needlesticks can result in serious health consequences. Attempt to find ways to eliminate your risk when working with sharp materials.

Report all accidents and injuries immediately to your supervisor or the business unit Environmental Health and Safety Manager or Specialist.

16. RELATED DOCUMENTS

1. Dimension Vista® Clinical Chemistry System Operator’s Manual
2. Dimension Vista® Calibration/Verification Procedure
3. Dimension Vista® Cal Accept Guidelines
4. Dimension Vista® Calibration summary
5. Dimension Vista® Sample Processing, Startup and Maintenance procedure
6. Laboratory Quality Control Program
7. QC Schedule for Siemens Dimension Vista®
8. Laboratory Safety Manual
9. Material Safety Data Sheets (MSDS)
10. Dimension Vista® Limits Chart (AG.F200)
11. Quest Diagnostics Records Management Procedure
12. Dimension Vista® System Error Messages Chart
13. Centrifuge Use, Maintenance and Functions Checks (Lab policy)
14. Hemolysis, Icteria and Lipemia Interference (Lab policy)
15. Repeat Testing Requirement (Lab policy)
16. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business_Groups/Medical/qc/docs/qc_bpt_tea.xls
17. Current package insert ALPI Flex® Reagent Cartridge K2115

17. REFERENCES

1. Ghoshal, Amit K. and Soldin, Steven J., Evaluation of the Dade Behring Dimension® RxL: Integrated chemistry system-pediatric reference ranges. Clinica Chimica Acta 2003; 331:144.
2. Package Insert, ALPI Flex® Reagent Cartridge K2115, Siemens Healthcare Diagnostics Inc., 02/12/2013.
3. Package Insert, ALPI CAL, Siemens Healthcare Diagnostics Inc., 04/2013.
4. Package Insert, Unassayed Liquichek Chemistry Controls, Bio-Rad Laboratories, 01/2013.
5. Package Insert, Enzyme Diluent, Siemens Healthcare Diagnostics Inc., 03/2008.


18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval

19. ADDENDA

None


Form revised 3/31/00



DIMENSION VISTA® LIMITS CHART

- Shady Grove Adventist Hospital
- Washington Adventist Hospital

ANALYTE	UNITS	INSTRUMENT DILUTION FACTOR	MAXIMUM RANGE AFTER ON BOARD DILUTION	MAXIMUM OFF BOARD DILUTION	CLINICALLY REPORTABLE RANGE (CRR)	DILUENT	SPECIAL DILUTION ON VISTA	S G A H	W A H
ACTM	µg/mL	2	2.0 - 600.0	3	2.0 - 900.0	Drug 2 Cal Level 1, or Drug Free Serum	N/A	x	x
ALB	g/dL	4	0.0 - 32.0	Not Available	0.0 - 32.0	Do NOT Dilute	N/A	x	x
ALC	mg/dL	4	3 - 1,200	Not Available	3 - 1,200	Do NOT Dilute	N/A	x	x
ALPI	U/L	2.33	10 - 2,330	10	10 - 10,000	Enzyme Diluent	N/A	x	x
ALTI	U/L	3.5	6 - 3,500	Not Available	6 - 10,000	Do NOT Dilute	10	x	x
AMON	µmol/L	2	10 - 1,500	3	10 - 2,250	Water	N/A	x	x
AMY	U/L	2	2 - 1,300	10	2 - 6,500	Enzyme Diluent	N/A	x	x
AST	U/L	2	3 - 2,000	Not Available	3 - 10,000	Do NOT Dilute	10	x	x
BUN	mg/dL	4	1 - 600	Not Available	1 - 600	Do NOT Dilute	N/A	x	x
CA	mg/dL	2	5.0 - 30.0	3	5.0 - 45.0	Water	N/A	x	x
CHOL	mg/dL	4	50 - 2,400	5	50 - 3,000	Water	N/A	x	x
CKI	U/L	7	7 - 7000	40	7 - 40,000	Water	N/A	x	x
CL	mmol/L	Not Available	50 - 200	Not Available	50 - 200	Do NOT Dilute	N/A	x	x
CRBM	µg/mL	4	0.5 - 80.0	Not Available	0.5 - 80.0	Do NOT Dilute	N/A	x	x
CREA	mg/dL	2	0.1 - 40.0	3	0.1 - 60.0	Water	N/A	x	x
CRP	mg/dL	20	0.3 - 380.0	Not Available	0.3 - 380.0	Do NOT Dilute	N/A	x	x
CTNI	ng/mL	5	0.02 - 200.00	Not Available	0.02 - 200.00	Do NOT Dilute	N/A	x	x
DBIL	mg/dL	4	0.1 - 64.0	5	0.1 - 80.0	Water	N/A	x	x
DGNA	ng/mL	Not Available	0.06 - 5.00	10	0.06 - 50.00	Drug 4 Cal. Level 1 or Digoxin-Free Serum	N/A	x	x
ECO2	mmol/L	Not Available	1 - 45	2	1 - 90	Water	N/A	x	x
FT4	ng/dL	Not Available	0.10 - 8.00	Not Available	0.10 - 8.00	Do NOT Dilute	N/A	x	x
GENT	µg/mL	4	0.2 - 48.0	Not Available	0.2 - 48.0	Do NOT Dilute	N/A	x	x
GGT	U/L	2	3 - 1,600	20	3 - 16,000	Enzyme Diluent	N/A	x	x
GLUC	mg/dL	4	1 - 2,000	5	1 - 2,500	Water	N/A	x	x
HCG	mIU/mL	200	1 - 200,000	1000	1 - 1,000,000	Water	N/A	x	x
HDLC	mg/dL	4	3 - 600	Not Available	3 - 600	Do NOT Dilute	N/A	x	x
K	mmol/L	Not Available	1.0 - 10.0	Not Available	1.0 - 10.0	Do NOT Dilute	N/A	x	x
LA	mmol/L	4	0.1 - 60.0	Not Available	0.1 - 60.0	Do NOT Dilute	N/A	x	x
LDI	U/L	4	6 - 4,000	20	6 - 20,000	Enzyme Diluent	N/A	x	x
LI	mmol/L	Not Available	0.20 - 3.00	3	0.20 - 9.00	Lithium Free Serum	N/A	x	x
LIPL	U/L	20	10 - 30,000	Not Available	10 - 30,000	Do NOT Dilute	N/A	x	x
MG	mg/dL	2	0.2 - 40.0	3	0.2 - 60.0	Water	N/A	x	x
MMB	ng/mL	20	0.5 - 6,000.0	Not Available	0.5 - 6,000.0	Do NOT Dilute	N/A	x	x
MYO	ng/mL	20	1 - 20,000	Not Available	1 - 20,000	Do NOT Dilute	N/A	x	x



DIMENSION VISTA® LIMITS CHART

- Shady Grove Adventist Hospital
- Washington Adventist Hospital

ANALYTE	UNITS	INSTRUMENT DILUTION FACTOR	MAXIMUM RANGE AFTER ON BOARD DILUTION	MAXIMUM OFF BOARD DILUTION	CLINICALLY REPORTABLE RANGE (CRR)	DILUENT	SPECIAL DILUTION ON VISTA	S G A H	W A H
NA	mmol/L	Not Available	50 - 200	Not Available	50 - 200	Do NOT Dilute	N/A	x	x
PHNO	µg/mL	4	2.1 - 320.0	Not Available	2.1 - 320.0	Do NOT Dilute	N/A	x	x
PHOS	mg/dL	2	0.1 - 18.0	5	0.1 - 45.0	Water	N/A	x	x
PTN	µg/mL	4	0.4 - 160.0	Not Available	0.4 - 160.0	Do NOT Dilute	N/A	x	x
SAL	mg/dL	3	1.7 - 300.0	Not Available	1.7 - 300.0	Do NOT Dilute	N/A	x	x
TBIL	mg/dL	4	0.1 - 100.0	5	0.1 - 125.0	Water	N/A	x	x
TGL	mg/dL	4	2 - 4,000	5	2- 5,000	Water	N/A	x	x
THEO	µg/mL	4	2.0 - 160.0	Not Available	2.0 - 160.0	Do NOT Dilute	N/A	x	x
TOBR	µg/mL	4	0.3 - 48.0	Not Available	0.3 - 48.0	Do NOT Dilute	N/A	x	x
TP	g/dL	2	0.0 - 24.0	3	0.0 - 36.0	Water	N/A	x	x
TSH	µIU/mL	5	0.01 - 500.00	Not Available	0.01 - 500.00	Do NOT Dilute	N/A	x	x
UCFP (CSF)	mg/dL	1.84	5 - 460	10	5 - 2500	Water	N/A	x	x
URCA	mg/dL	4	0.2 - 60.0	5	0.2 - 75.0	Water	N/A	x	x
VALP	µg/mL	2	3.0 - 300.0	3	3.0- 450.0	Drug 2 Cal Level 1, Drug Free serum, or Water	N/A	x	x
VANC	µg/mL	Not Available	0.8 - 50.0	3	0.8 - 150.0	Drug Cal 2 Level 1, Drug Free Serum, or Water	N/A	x	x

ANALYTE	UNITS	INSTRUMENT DILUTION FACTOR	MAXIMUM RANGE AFTER ON BOARD DILUTION	MAXIMUM OFF BOARD DILUTION	CLINICALLY REPORTABLE RANGE (CRR)	DILUENT	S G A H	W A H
Urine CREA	mg/dL	Not Available	0.1 - 200.0	3	0.1 - 600.0	Enzyme Diluent	x	x
Urine K	mmol/L	Not Available	1.0 - 300.0	Do Not Dilute	1.0 - 300.0	Do Not Dilute	x	x
Urine SOD	mmol/L	Not Available	5 - 300	Do Not Dilute	5 - 300	Do Not Dilute	x	x
UCFP (urine only)	mg/dL	1.84	5 - 460	10	5 - 2500	Water	x	x